Abbott Laboratories Completes Final Step in Acquisition of Vysis, Inc.

06-Dec-2001

Abbott Park, Illinois, December 5, 2001 — Abbott Laboratories announced that it has completed the final step in acquiring 100 percent of the outstanding shares of Vysis, Inc. (Nasdaq:VYSI). Vysis is a leading genomic disease management company that develops and markets clinical laboratory products, which provide information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases.

At the conclusion of its successful cash tender offer on Nov. 30, 2001, Abbott owned approximately 98.6 percent of Vysis' shares. As the final step in the acquisition process, Vysis has been acquired as a wholly owned subsidiary of Abbott through a short-form merger.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances